SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage
biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today
announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 9th, 2018, at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco.
A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website
at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia
website for 90 days following the conference.
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and
commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is
on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from
biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a
pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic
cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly
MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical
studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial. MYK-491, MyoKardia’s second product
candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac
contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers. A cornerstone of the
MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical
and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s
mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.
Contacts
Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Steven Cooper (Media)
Edelman
415-486-3264
steven.cooper@edelman.com
